abstract |
A DPP-4 inhibitor for use in wound healing in diabetic patients, wherein said DPP-4 inhibitor is selected from the group consisting of 1-[(4-methylquinazolin-2-yl)methyl]-3- methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine, 1-[([1,5]naphthyridin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine, 1-[(quinazolin-2-yl)methyl]-3-methyl-7 -(2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine, 2-((R)-3-aminopiperidin-1-yl)-3-(but-2 -inyl)-5-(4-methylquinazolin-2-ylmethyl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one, 1-[(3-cyanoquinolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine, 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-[(S)-(2-aminopropyl)methylamino]-xanthine, 1-[(4,6-dimethylpyrimidin-2-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine and 1-[(quinoxalin-6-yl)methyl]-3-methyl-7-( 2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine, or a pharmaceutically acceptable salt thereof; wherein said DPP-4 inhibitor is administered topically. |